Business
Labcorp provides diagnostic laboratory testing and biopharmaceutical laboratory services.
Labcorp: Revenue grew 7.2% to $13.952B from $13.009B. Net income grew 17.5% to $876.5M from $746M. Free cash flow grew 10.0% to $1.206B from $1.096B. Operating margin expanded 157 bps to 9.92%. Labcorp's annual comparison also shows inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 7.2%OK
- Profitability — Net income grew 17.5% to $876.5M from $746MOK
- Cash flow — Free cash flow grew 10.0% to $1.206B from $1.096BOK
- Margins — Operating margin expanded 157 bps to 9.92%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 18 salesWatch
Where the revenue comes from
Fiscal 2025, as LABCORP HOLDINGS INC. reports it. History and quarterly detail are in the app.
- Diagnostics$10.9B
- Biopharma Laboratory Services$3.1B
Leadership changes
From LABCORP HOLDINGS INC.'s own filings, the day they're filed.
- John H. Sampson · Directors · appointmenteff. 2026-02-09
- Victor Bulto · director · appointmenteff. 2025-12-01
- Julia Wang · Chief Financial Officer · departureeff. 2025-04-30
Latest filings
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about LABCORP HOLDINGS INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.